Login to Your Account



Agennix Nets $105M in Share Offer to Develop Talactoferrin

By Cormac Sheridan


Monday, October 4, 2010
Agennix AG grossed €78.4 million (US$107.8 million) – about €76 million net of expenses – in a combined rights offering and private placement that will enable it to continue development of its lead drug candidate, talactoferrin, which is being studied in cancer and sepsis. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription